🔬 Their collaboration combines MaxCyte’s ExPERT™ platform with Ori’s IRO™ platform.
⚙️ The goal is to optimize cell yields and streamline production timelines.
👥 They will initially test CD19 CAR expression in T cells.
🚀 This partnership aims to accelerate availability of advanced treatments for patients.
Introduction:
MaxCyte and Ori Biotech have announced a strategic collaboration to enhance the efficiency and scalability of autologous cellular therapy manufacturing. This partnership aims to leverage MaxCyte’s ExPERT™ platform and Ori’s IRO® system to optimize manufacturing processes in the rapidly evolving field of cell therapy.
- The collaboration combines MaxCyte’s Flow Electroporation® technology with Ori’s advanced IRO® platform, focusing on improving productivity in cell therapy manufacturing.
- Initial evaluations will use CD19 CAR expression via CRISPR knock-in in activated T cells to assess the optimization capabilities of the IRO platform.
- MaxCyte’s technology enables the transfection of cells at clinical scale, while Ori’s IRO platform enhances automation and fluid handling in cell culture processes.
- This partnership is designed to accelerate the development of gene-edited T cells and bridge the gap between laboratory capabilities and clinical demand.
- Both companies emphasize their commitment to improving the manufacturing processes, ultimately enabling timely access to transformative cellular therapies for patients.
Conclusion:
This collaboration between MaxCyte and Ori Biotech signifies a significant step forward in addressing the challenges faced in cell therapy manufacturing. By integrating their respective technologies, they aim to scale up the production of clinically relevant cell therapies, enhancing the efficiency and reliability of these transformative treatments for patients. The implications of this partnership could pave the way for more expedited and affordable access to life-saving therapies in the future.
